Clinical Cancer Research Joint Metastasis Research Society-AACR Conference on Metastasis Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Voorhees, P. M.
Right arrow Articles by Orlowski, R. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voorhees, P. M.
Right arrow Articles by Orlowski, R. Z.
Related Collections
Right arrow Therapeutics and Targets
Right arrow Therapeutics and Targets: Experimental Therapeutics– Small Molecules
Clinical Cancer Research Vol. 9, 6316-6325, December 15, 2003
© 2003 American Association for Cancer Research

Review

The Proteasome as a Target for Cancer Therapy

Peter M. Voorhees12, E. Claire Dees12, Bert O’Neil12 and Robert Z. Orlowski12

1 The Lineberger Comprehensive Cancer Center and
2 Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

The proteasome is a multicatalytic proteinase complex responsible for the degradation of most intracellular proteins, including proteins crucial to cell cycle regulation and programmed cell death, or apoptosis. In preclinical cancer models, proteasome inhibitors induce apoptosis, have in vivo antitumor efficacy, and sensitize malignant cells and tumors to the proapoptotic effects of conventional chemotherapeutics and radiation therapy. Interestingly, transformed cells display greater susceptibility to proteasome inhibition than nonmalignant cells. Therefore, proteasome inhibition holds promise as a novel approach to the treatment of cancer. Inhibitors of the proteasome impact on cells in part through down-regulation of nuclear factor {kappa}B, but also through modulation of cell cycle proteins and other pro- and antiapoptotic pathways. Bortezomib (VELCADE; formerly PS-341), the first such inhibitor to undergo clinical testing, has demonstrated impressive antitumor activity and manageable toxicities in Phase I and II trials both as a single agent, and in combination with other drugs. It has been approved recently by the Food and Drug Administration for therapy of patients with multiple myeloma who have received at least two prior regimens and progressed on the last of these. Ongoing preclinical evaluations of the mechanisms that underlie the antitumor effects of proteasome inhibitors, and clinical trials in a variety of tumor types, will allow additional refinement of the role these agents will play in cancer therapy. Below we discuss the rationale behind targeting the proteasome for cancer therapy, and review the preclinical and clinical data on proteasome inhibitors alone, and in combination with conventional chemotherapeutics.




This article has been cited by other articles:


Home page
 Ann OncolHome page
J. E. Rosenberg, S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. J. Hohl, F. Millard, D. F. Bajorin, E. J. Small, and For the Cancer and Leukemia Group B
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
Ann. Onc., May 1, 2008; 19(5): 946 - 950.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Z. Orlowski and D. J. Kuhn
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Clin. Cancer Res., March 15, 2008; 14(6): 1649 - 1657.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. Leblond, F. Le Pessot, A. Hubert-Buron, C. Duclos, J. Vuichoud, M. Faure, D. Breuille, P. Dechelotte, and M. Coeffier
Chemotherapy-Induced Mucositis Is Associated with Changes in Proteolytic Pathways
Experimental Biology and Medicine, February 1, 2008; 233(2): 219 - 228.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Shi, G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy Jr, B. Barlogie, et al.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
Blood, February 1, 2008; 111(3): 1309 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Z. Orlowski, A. Nagler, P. Sonneveld, J. Blade, R. Hajek, A. Spencer, J. San Miguel, T. Robak, A. Dmoszynska, N. Horvath, et al.
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
J. Clin. Oncol., September 1, 2007; 25(25): 3892 - 3901.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist, June 1, 2007; 12(6): 664 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. W. Small, Y. Y. Shi, L. S. Higgins, and R. Z. Orlowski
Mitogen-Activated Protein Kinase Phosphatase-1 Is a Mediator of Breast Cancer Chemoresistance
Cancer Res., May 1, 2007; 67(9): 4459 - 4466.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J.-P. Armand, A. K. Burnett, J. Drach, J.-L. Harousseau, B. Lowenberg, and J. San Miguel
The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib
Oncologist, March 1, 2007; 12(3): 281 - 290.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al.
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol., October 20, 2006; 24(30): 4867 - 4874.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Shimada, M. Nakamura, S. Matsuyoshi, E. Ishida, and N. Konishi
Specific positive and negative effects of FLIP on cell survival in human prostate cancer
Carcinogenesis, July 1, 2006; 27(7): 1349 - 1357.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. R. Hosler, S.-T. Wang-Su, and B. J. Wagner
Role of the Proteasome in TGF-{beta} Signaling in Lens Epithelial Cells
Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 2045 - 2052.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. A. Gomez, A. de las Pozas, and C. Perez-Stable
Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1216 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. H. Y. Yeung, D.-C. Huang, and F. A. Sinicrope
PS-341 (Bortezomib) Induces Lysosomal Cathepsin B Release and a Caspase-2-dependent Mitochondrial Permeabilization and Apoptosis in Human Pancreatic Cancer Cells
J. Biol. Chem., April 28, 2006; 281(17): 11923 - 11932.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. F. Kisselev, A. Callard, and A. L. Goldberg
Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate
J. Biol. Chem., March 31, 2006; 281(13): 8582 - 8590.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, A. Glasmacher, S. Jagannath, S. Lonial, R. Z. Orlowski, P. Sonneveld, and H. Ludwig
A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma
Oncologist, January 1, 2006; 11(1): 51 - 61.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-L. Law, K. A. Gordon, J. Collier, K. Klussman, J. A. McEarchern, C. G. Cerveny, B. J. Mixan, W. P. Lee, Z. Lin, P. Valdez, et al.
Preclinical Antilymphoma Activity of a Humanized Anti-CD40 Monoclonal Antibody, SGN-40
Cancer Res., September 15, 2005; 65(18): 8331 - 8338.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Hachem and R. B. Gartenhaus
Oncogenes as molecular targets in lymphoma
Blood, September 15, 2005; 106(6): 1911 - 1923.
[Full Text] [PDF]

Home page
 JCOHome page
A.L. Hamilton, J.P. Eder, A.C. Pavlick, J.W. Clark, L. Liebes, R. Garcia-Carbonero, A. Chachoua, D.P. Ryan, V. Soma, K. Farrell, et al.
Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle
J. Clin. Oncol., September 1, 2005; 23(25): 6107 - 6116.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
E. W. Newcomb, M. A. Ali, T. Schnee, L. Lan, Y. Lukyanov, M. Fowkes, D. C. Miller, and D. Zagzag
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1{alpha} expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy
Neuro-oncol, July 1, 2005; 7(3): 225 - 235.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
L. Chen and K. Madura
Increased Proteasome Activity, Ubiquitin-Conjugating Enzymes, and eEF1A Translation Factor Detected in Breast Cancer Tissue
Cancer Res., July 1, 2005; 65(13): 5599 - 5606.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y.-W. Chen, S.-C. Huang, S.-Y. Lin-Shiau, and J.-K. Lin
Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1
Carcinogenesis, July 1, 2005; 26(7): 1296 - 1306.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Dispenzieri
Bortezomib for Myeloma -- Much Ado about Something
N. Engl. J. Med., June 16, 2005; 352(24): 2546 - 2548.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. K. Dy, J. P. Thomas, G. Wilding, L. Bruzek, S. Mandrekar, C. Erlichman, D. Alberti, K. Binger, H. C. Pitot, S. R. Alberts, et al.
A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
Clin. Cancer Res., May 1, 2005; 11(9): 3410 - 3416.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Barnes, F. Li, A. H. Talukder, and R. Kumar
Growth Factor Regulation of a 26S Proteasomal Subunit in Breast Cancer
Clin. Cancer Res., April 15, 2005; 11(8): 2868 - 2874.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Z. Orlowski, P. M. Voorhees, R. A. Garcia, M. D. Hall, F. J. Kudrik, T. Allred, A. R. Johri, P. E. Jones, A. Ivanova, H. W. Van Deventer, et al.
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
Blood, April 15, 2005; 105(8): 3058 - 3065.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H.-Y. Jiang and R. C. Wek
Phosphorylation of the {alpha}-Subunit of the Eukaryotic Initiation Factor-2 (eIF2{alpha}) Reduces Protein Synthesis and Enhances Apoptosis in Response to Proteasome Inhibition
J. Biol. Chem., April 8, 2005; 280(14): 14189 - 14202.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Storling, N. Allaman-Pillet, A. E. Karlsen, N. Billestrup, C. Bonny, and T. Mandrup-Poulsen
Antitumorigenic Effect of Proteasome Inhibitors on Insulinoma Cells
Endocrinology, April 1, 2005; 146(4): 1718 - 1726.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
P. Boya, R.-A. Gonzalez-Polo, N. Casares, J.-L. Perfettini, P. Dessen, N. Larochette, D. Metivier, D. Meley, S. Souquere, T. Yoshimori, et al.
Inhibition of Macroautophagy Triggers Apoptosis
Mol. Cell. Biol., February 1, 2005; 25(3): 1025 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
S. O'Connor, S. Shumway, and S. Miyamoto
Inhibition of I{kappa}B{alpha} Nuclear Export as an Approach to Abrogate Nuclear Factor-{kappa}B-Dependent Cancer Cell Survival
Mol. Cancer Res., January 1, 2005; 3(1): 42 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. W. Small, Y. Y. Shi, N. A. Edmund, S. Somasundaram, D. T. Moore, and R. Z. Orlowski
Evidence That Mitogen-Activated Protein Kinase Phosphatase-1 Induction by Proteasome Inhibitors Plays an Antiapoptotic Role
Mol. Pharmacol., December 1, 2004; 66(6): 1478 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. Duan, L. Gao, L. J. Druhan, W.-G. Zhu, C. Morrison, G. A. Otterson, and M. A. Villalona-Calero
Expression of Pirh2, a Newly Identified Ubiquitin Protein Ligase, in Lung Cancer
J Natl Cancer Inst, November 17, 2004; 96(22): 1718 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Xia, M. Roundtree, A. Merikhi, X. Lu, S. Shentu, and G. LeSage
Degradation of the Apical Sodium-dependent Bile Acid Transporter by the Ubiquitin-Proteasome Pathway in Cholangiocytes
J. Biol. Chem., October 22, 2004; 279(43): 44931 - 44937.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. K. Saville, A. Sparks, D. P. Xirodimas, J. Wardrop, L. F. Stevenson, J.-C. Bourdon, Y. L. Woods, and D. P. Lane
Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo
J. Biol. Chem., October 1, 2004; 279(40): 42169 - 42181.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Q. Xu, M. Farah, J. M. Webster, and R. J.H. Wojcikiewicz
Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor
Mol. Cancer Ther., October 1, 2004; 3(10): 1263 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Adrain, E. M. Creagh, S. P. Cullen, and S. J. Martin
Caspase-dependent Inactivation of Proteasome Function during Programmed Cell Death in Drosophila and Man
J. Biol. Chem., August 27, 2004; 279(35): 36923 - 36930.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
R. E. Brown, M. Lun, J. W. Prichard, T. M. Blasick, and P. L. Zhang
Morphoproteomic and Pharmacoproteomic Correlates in Hormone-Receptor-Negative Breast Carcinoma Cell Lines
Ann. Clin. Lab. Sci., July 1, 2004; 34(3): 251 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. A. Bunn Jr.
The Potential Role of Proteasome Inhibitors in the Treatment of Lung Cancer
Clin. Cancer Res., June 15, 2004; 10(12): 4263S - 4265S.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. Dmitrovsky
Tissue Microarrays for Hypothesis Generation
J Natl Cancer Inst, February 18, 2004; 96(4): 248 - 249.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2003 by the American Association for Cancer Research.